- Home
- CNTA vs GBDC Comparison
CNTA vs GBDC Comparison
Compare CNTA & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTA | GBDC |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CNTA | GBDC |
|---|---|---|
| Price | $21.97 | $13.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $37.70 | $14.83 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 11-05-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 11.57% |
| EPS Growth | N/A | ★ 4.09 |
| EPS | N/A | ★ 1.42 |
| Revenue | $15,000,000.00 | ★ $870,777,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.52 |
| Revenue Growth | ★ 118.88 | 20.16 |
| 52 Week Low | $9.60 | $12.68 |
| 52 Week High | $30.58 | $16.01 |
Technical Indicators
Market Signals| Indicator | CNTA | GBDC |
|---|---|---|
| Relative Strength Index (RSI) | 28.32 | 53.66 |
| Support Level | $22.15 | $13.44 |
| Resistance Level | $23.69 | $13.94 |
| Average True Range (ATR) | 1.03 | 0.23 |
| MACD | -0.36 | 0.03 |
| Stochastic Oscillator | 8.52 | 83.72 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.